Literature DB >> 17522228

Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies.

Esther D Quakkelaar1, Floris P J van Alphen, Brigitte D M Boeser-Nunnink, Ad C van Nuenen, Ralph Pantophlet, Hanneke Schuitemaker.   

Abstract

The ability of the broadly neutralizing human immunodeficiency virus type 1 (HIV-1) specific human monoclonal antibodies (MAbs) b12, 2G12, 2F5, and 4E10 to neutralize recently transmitted viruses has not yet been explored in detail. We investigated the neutralization sensitivity of subtype B HIV-1 variants obtained from four primary HIV infection cases and six transmission couples (four homosexual and two parenteral) to these MAbs. Sexually transmitted HIV-1 variants isolated within the first 2 months after seroconversion were generally sensitive to 2F5, moderately resistant to 4E10 and b12, and initially resistant but later more sensitive to 2G12 neutralization. In the four homosexual transmission couples, MAb neutralization sensitivity of HIV in recipients did not correlate with the MAb neutralization sensitivity of HIV from their source partners, whereas the neutralization sensitivity of donor and recipient viruses involved in parenteral transmission was more similar. For a fraction (11%) of the HIV-1 variants analyzed here, neutralization by 2G12 could not be predicted by the presence of N-linked glycosylation sites previously described to be involved in 2G12 binding. Resistance to 2F5 and 4E10 neutralization did also not correlate with mutations in the respective core epitopes. Overall, we observed that the neutralization resistance of recently transmitted subtype B HIV-1 variants was relatively high. Although 8 of 10 patients had viruses that were sensitive to neutralization by at least one of the four broadly neutralizing antibodies studied, 4 of 10 patients harbored at least one virus variant that seemed resistant to all four antibodies. Our results suggest that vaccine antigens that only elicit antibodies equivalent to b12, 2G12, 2F5, and 4E10 may not be sufficient to protect against all contemporary HIV-1 variants and that additional cross-neutralizing specificities need to be sought.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17522228      PMCID: PMC1951377          DOI: 10.1128/JVI.02816-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  DAMBE: software package for data analysis in molecular biology and evolution.

Authors:  X Xia; Z Xie
Journal:  J Hered       Date:  2001 Jul-Aug       Impact factor: 2.645

2.  Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection.

Authors:  T W Baba; V Liska; R Hofmann-Lehmann; J Vlasak; W Xu; S Ayehunie; L A Cavacini; M R Posner; H Katinger; G Stiegler; B J Bernacky; T A Rizvi; R Schmidt; L R Hill; M E Keeling; Y Lu; J E Wright; T C Chou; R M Ruprecht
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

3.  A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.

Authors:  G Stiegler; R Kunert; M Purtscher; S Wolbank; R Voglauer; F Steindl; H Katinger
Journal:  AIDS Res Hum Retroviruses       Date:  2001-12-10       Impact factor: 2.205

4.  Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.

Authors:  Maxime Moulard; Sanjay K Phogat; Yuuei Shu; Aran F Labrijn; Xiaodong Xiao; James M Binley; Mei-Yun Zhang; Igor A Sidorov; Christopher C Broder; James Robinson; Paul W H I Parren; Dennis R Burton; Dimiter S Dimitrov
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-07       Impact factor: 11.205

5.  Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.

Authors:  P W Parren; P A Marx; A J Hessell; A Luckay; J Harouse; C Cheng-Mayer; J P Moore; D R Burton
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

Review 6.  Prospects for vaccine protection against HIV-1 infection and AIDS.

Authors:  Norman L Letvin; Dan H Barouch; David C Montefiori
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

7.  Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection.

Authors:  D C Montefiori; T S Hill; H T Vo; B D Walker; E S Rosenberg
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

8.  Reversal of human immunodeficiency virus type 1 IIIB to a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course.

Authors:  T Beaumont; A van Nuenen; S Broersen; W A Blattner; V V Lukashov; H Schuitemaker
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

9.  The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.

Authors:  Rogier W Sanders; Miro Venturi; Linnea Schiffner; Roopa Kalyanaraman; Hermann Katinger; Kenneth O Lloyd; Peter D Kwong; John P Moore
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

10.  Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin.

Authors:  Ming Zhang; Brian Gaschen; Wendy Blay; Brian Foley; Nancy Haigwood; Carla Kuiken; Bette Korber
Journal:  Glycobiology       Date:  2004-06-02       Impact factor: 4.313

View more
  17 in total

1.  Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity.

Authors:  Zelda Euler; Tom L G M van den Kerkhof; Marit J van Gils; Judith A Burger; Diana Edo-Matas; Pham Phung; Terri Wrin; Hanneke Schuitemaker
Journal:  J Virol       Date:  2011-12-07       Impact factor: 5.103

2.  Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemic.

Authors:  Zelda Euler; Evelien M Bunnik; Judith A Burger; Brigitte D M Boeser-Nunnink; Marlous L Grijsen; Jan M Prins; Hanneke Schuitemaker
Journal:  J Virol       Date:  2011-05-11       Impact factor: 5.103

3.  Longer V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies.

Authors:  Marit J van Gils; Evelien M Bunnik; Brigitte D Boeser-Nunnink; Judith A Burger; Marijke Terlouw-Klein; Naomi Verwer; Hanneke Schuitemaker
Journal:  J Virol       Date:  2011-05-18       Impact factor: 5.103

4.  HIV-1 blocks the signaling adaptor MAVS to evade antiviral host defense after sensing of abortive HIV-1 RNA by the host helicase DDX3.

Authors:  Sonja I Gringhuis; Nina Hertoghs; Tanja M Kaptein; Esther M Zijlstra-Willems; Ramin Sarrami-Forooshani; Joris K Sprokholt; Nienke H van Teijlingen; Neeltje A Kootstra; Thijs Booiman; Karel A van Dort; Carla M S Ribeiro; Agata Drewniak; Teunis B H Geijtenbeek
Journal:  Nat Immunol       Date:  2016-12-26       Impact factor: 25.606

5.  Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.

Authors:  James M Binley; Elizabeth A Lybarger; Emma T Crooks; Michael S Seaman; Elin Gray; Katie L Davis; Julie M Decker; Diane Wycuff; Linda Harris; Natalie Hawkins; Blake Wood; Cory Nathe; Douglas Richman; Georgia D Tomaras; Frederic Bibollet-Ruche; James E Robinson; Lynn Morris; George M Shaw; David C Montefiori; John R Mascola
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

6.  Interactions between lipids and human anti-HIV antibody 4E10 can be reduced without ablating neutralizing activity.

Authors:  Hengyu Xu; Likai Song; Mikyung Kim; Margaret A Holmes; Zane Kraft; George Sellhorn; Ellis L Reinherz; Leonidas Stamatatos; Roland K Strong
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

7.  Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection.

Authors:  Evelien M Bunnik; Linaida Pisas; Ad C van Nuenen; Hanneke Schuitemaker
Journal:  J Virol       Date:  2008-06-04       Impact factor: 5.103

8.  Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors.

Authors:  Marit J van Gils; Evelien M Bunnik; Judith A Burger; Yodit Jacob; Becky Schweighardt; Terri Wrin; Hanneke Schuitemaker
Journal:  J Virol       Date:  2010-01-13       Impact factor: 5.103

9.  High prevalence of neutralizing activity against multiple unrelated human immunodeficiency virus type 1 (HIV-1) subtype B variants in sera from HIV-1 subtype B-infected individuals: evidence for subtype-specific rather than strain-specific neutralizing activity.

Authors:  Marit J van Gils; Diana Edo-Matas; Becky Schweighardt; Terri Wrin; Hanneke Schuitemaker
Journal:  J Gen Virol       Date:  2009-09-30       Impact factor: 3.891

10.  Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones.

Authors:  Joshua Baalwa; Shuyi Wang; Nicholas F Parrish; Julie M Decker; Brandon F Keele; Gerald H Learn; Ling Yue; Eugene Ruzagira; Deogratius Ssemwanga; Anatoli Kamali; Pauli N Amornkul; Matt A Price; John C Kappes; Etienne Karita; Pontiano Kaleebu; Eduard Sanders; Jill Gilmour; Susan Allen; Eric Hunter; David C Montefiori; Barton F Haynes; Emmanuel Cormier; Beatrice H Hahn; George M Shaw
Journal:  Virology       Date:  2012-11-01       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.